GeoVax Labs (GOVX) Capital Expenditures (2013 - 2025)

GeoVax Labs (GOVX) posted quarterly Capital Expenditures of $10718.0 for Q2 2025, down 36.56% quarter-over-quarter from $16894.0 in Q1 2025.

GeoVax Labs (GOVX) Capital Expenditures (2013 - 2025) Analysis & Trends

GeoVax Labs (GOVX) has reported Capital Expenditures for 11 consecutive years, with $10718.0 the latest figure, recorded in Q2 2025.

In Q2 2025, Capital Expenditures changed N/A year-over-year to $10718.0; the TTM figure through Dec 2025 stood at $27612.0 (up 33.69% YoY), while the FY2025 annual figure was $27612.0, up 33.69% from the prior year.
Capital Expenditures declined to $10718.0 in Q2 2025 per GOVX's latest filing, from $16894.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $62186.0 in Q1 2022 and bottomed at $6192.0 in Q3 2023.
Historically, Capital Expenditures has averaged $25380.6 across 5 years, with a median of $20197.0 in 2022.
Annual changes were most pronounced in 2021 — Capital Expenditures soared 1025.06% — and 2023, when it plunged 88.06%.
GeoVax Labs' Capital Expenditures stood at $27789.0 in 2021, then jumped by 86.67% to $51875.0 in 2022, then plunged by 63.47% to $18949.0 in 2023, then rose by 8.99% to $20653.0 in 2024, then slumped by 48.1% to $10718.0 in 2025.
Business Quant data shows GOVX's Capital Expenditures at $10718.0 in Q2 2025, $16894.0 in Q1 2025, and $20653.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	112.20 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	240.20 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	37.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	25.02 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	34.68 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-73.57 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.26 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	251.02 Mn
10	GeoVax Labs	2.88 Mn	-260,493.75	-	-

Download Data